|Bid||1.5000 x 900|
|Ask||4.8800 x 1000|
|Day's Range||1.7100 - 1.9400|
|52 Week Range||1.0400 - 5.2500|
|Beta (3Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...
Shares of thinly traded, nano-cap biotech Achieve Life Sciences Inc (NASDAQ: ACHV ) traded sharply higher Friday morning before paring those gains. Achieve, which develops Cytisinicline – a plant-based ...
Achieve Life Sciences, Inc. (ACHV) reported topline results from its Phase IIb Ongoing Research of Cytisinicline for Addiction (ORCA)-1 trial which was launched in October 2018. The study enrolled 254 subjects, employing six arms: four with active drug and two with placebo. The primary endpoint for the ORCA-1 study was the self-reported reduction in daily smoking.
Achieve Life Sciences, Inc. (ACHV) released its first quarter results for 2019 and filed the companion 10-Q on May 15, 2019. Since our previous update two months ago, the company announced the end of the ORCA-1 trial which is expected to produce topline results mid-year.
Achieve Life Sciences, Inc. (ACHV) announced that its final enrollee had completed their final visit in the Phase IIb ORCA-1 trial on Wednesday. As a reminder the ORCA-1 (Ongoing Research of Cytisinicline for Addiction) trial is evaluating the effectiveness of cytisinicline for smoking cessation. The trial was designed as a multicenter, double blind, placebo-controlled trial in adult smokers randomized in a 2:2:1 ratio at 1.5 mg, 3.0 mg and placebo.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
Achieve Life Sciences, Inc. (ACHV) released its financial results for 2018 and filed the companion 10-K for the year ending December 31, 2018 on March 14, 2019. An investor conference call was held following the release to discuss recent achievements and financial results. Since our initiation, the company initiated a maximum tolerated dose (MTD) trial to examine the feasibility of a higher dose as they move into a Phase III trial.
Achieve Life Sciences, Inc. (ACHV) is developing cytisinicline, historically known as cytisine, for nicotine addiction. Achieve has licensed cytisinicline for development and commercialization in the United States and most other geographies around the world including parts of Europe, the Middle East, Africa and Asia. The drug formulation has been used by over 20 million smokers in Central and Eastern Europe for smoking cessation and also in over 2,000 subjects in previously conducted investigator-led Phase 3 clinical trials.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in Achieve Life Sciences, Inc. (NASDAQ:ACHV)Read More...
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
After an impressive 48.8% gain last week by Achieve Life Sciences (NASDAQ:ACHV) stock, ACHV stock has given up nearly all of its gains this week. ACHV stock price jumped on Sept. 27 after the company reported the results of a clinical study, but the shares went on to lose practically all of their gains by Oct. 1. ACHV stated that a new formulation of its smoking cessation aid – cytisine – showed similar bioavailability when the subjects were fed and when they fasted.